Home

Dynavax Technologies Corp. (DVAX)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Dynavax Technologies Corp. (DVAX)

Go deeper and ask any question about DVAX

Company Performance

Current Price

as of Sep 13, 2024

$11.17

P/E Ratio

102.20

Market Cap

$1.46B

Description

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Metrics

Overview

  • HQEmeryville, CA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerDVAX
  • Price$11.17+1.82%

Trading Information

  • Market Cap$1.46B
  • Float99.51%
  • Average Daily Volume (1m)1,916,663
  • Average Daily Volume (3m)2,255,787
  • EPS$0.13

Company

  • Revenue$249.70M
  • Rev Growth (1yr)22.48%
  • Net Income$11.39M
  • Gross Margin83.76%
  • EBITDA Margin10.89%
  • EBITDA$8.04M
  • EV$1.25B
  • EV/Revenue5.02
  • P/E102.20
  • P/S6.91
Documents